CDK8/19-IN-4
CDK8/19-IN-4 is an orally active CDK8/19 inhibitor. CDK8/19-IN-4 directly binds to and inhibits CDK8/Cyclin C, and inhibits CDK19/Cyclin C. The IC50 values of CDK8/19-IN-4 for CDK8, CDK19, CDK7, and CDK6 are 24.5 nM, 38.6 nM, 412.5 nM, and 694.4 nM, respectively, and the Kd for CDK8 is 46.44 nM. CDK8/19-IN-4 promotes Treg differentiation through the STAT1 and TGF-β/Smad signaling pathways, reduces STAT1 phosphorylation and enhances Smad2/3 activation, and inhibits IL-17A/TNF-α-induced keratinocyte proliferation and inflammatory mediator production. CDK8/19-IN-4 alleviates skin inflammation in the IMQ-induced psoriasis-like model. CDK8/19-IN-4 can be used for research on psoriasis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C23H22N4O3S
- Molecular Weight:434.51
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle TNF Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
CDK8 24.5 nM (IC50) |
CDK8 46.44 nM (Kd) |
CDK19 38.6 nM (IC50) |
CDK6 694.4 nM (IC50) |
CDK7 412.5 |
TNF-α |
STAT1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
58.2 nM
|
Inhibition of TNF-alpha-induced NF-kB transcriptional activity in human HEK293 cells by luciferase reporter assay after 3 hrs incubation.
Inhibition of TNF-alpha-induced NF-kB transcriptional activity in human HEK293 cells by luciferase reporter assay after 3 hrs incubation.
|
42664599 |
In Vitro
CDK8/19-IN-4 (C4/LW-1) (3 hours) inhibits NF-κB transcriptional activity in 293T cells with an IC50 of 58.2 nM and reduces TNF-α-driven inflammatory cytokine secretion[1].
CDK8/19-IN-4 (0.1-0.5 μM; 5 days) promotes Treg differentiation through the STAT1/Smad signaling pathway and a CDK8-dependent mechanism (78.7% Foxp3+ at 500 nM)[1].
CDK8/19-IN-4 (0.5-2 μM; preincubation for 1 hour; stimulation for 24 hours) inhibits IL-17A/TNF-α-induced inflammatory responses in HaCaT keratinocytes[1].
CDK8/19-IN-4 directly binds CDK8-cyclin C with a KD of 46.44 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male, 6-8 weeks old, about 20 g)[1]
-
Dosage:5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:for 7 days
-
Result:Markedly alleviated IMQ-induced pathological skin features in a dose-dependent manner.
Significantly reduced erythema, scaling, and thickness scores and substantially decreased cumulative PASI scores; LW-1 exhibited improved efficacy relative to C46 under the tested conditions.
No significant changes in body weight were observed.
Attenuated IMQ-induced splenomegaly, as indicated by a reduced spleen index.
H&E staining showed that LW-1 alleviated epidermal hyperplasia, inflammatory cell infiltration, and skin thickening.
Immunohistochemical analysis of Ki-67 showed a pronounced reduction in keratinocyte proliferation after LW-1 administration.
In flow cytometry analysis, CD4+Foxp3+ Treg cells among CD4+ T cells were: IMQ 7.58%; LW-1 5 mg/kg 9.01%; LW-1 10 mg/kg 10.8%; LW-1 20 mg/kg 12.0%; control 13.1%.
Restored Treg populations in a dose-dependent manner, and at the high dose LW-1 showed superior effects relative to C46.
IMQ stimulation upregulated IL-6, TNF-α, CXCL1, and CXCL2 mRNA expression, while LW-1 markedly suppressed their expression in a dose-dependent manner.
ELISA showed that LW-1 significantly reduced serum protein levels of IL-6, TNF-α, CXCL1, and CXCL2.
Chemical Information
-
Molecular Weight 434.51
-
Formel C23H22N4O3S
-
SMILES
O=C(N1CCOCC1)NC2=CC=C(C3=CN=C(NC=C4C5=CSC=C5)C4=C3)C(OC)=C2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Naïve CD4+ T-cell subset differentiation/polarization
Naïve CD4+ T-cell subset differentiation/polarization is an in vitro assay in which purified naïve CD4+ T cells are activated through TCR and CD28 costimulation and cultured with defined cytokines and neutralizing antibodies to generate Th0, Th1, Th2, Th17, or induced Treg-like populations. Differentiation is detected by subset-associated cytokines and transcription factors: IFN-γ/T-bet for Th1, IL-4/GATA3 for Th2, IL-17A/RORγt for Th17, and Foxp3 for induced Treg cells. The assay readout is usually generated by intracellular cytokine staining after restimulation, transcription-factor staining by flow cytometry, ELISA of secreted cytokines, or gene-expression analysis. The result reflects cytokine-directed lineage commitment or polarization rather than antigen-specific immune protection by itself.
-
Imiquimod-Induced Psoriasiform Dermatitis
Imiquimod (IMQ)-induced psoriasiform dermatitis is a widely used murine model in which topical application of IMQ, a Toll-like receptor 7 (TLR7) agonist, triggers innate immune activation in the skin and induces a psoriasis-like inflammatory cascade characterized by epidermal hyperplasia, immune cell infiltration, and cytokine production dominated by the IL-23/IL-17 axis. This inflammatory response is mediated through activation of dendritic cells and downstream induction of IL-23, IL-17A, IL-22, and related pro-inflammatory mediators, recapitulating key features of human plaque psoriasis and enabling mechanistic and therapeutic studies. The model is commonly induced using Aldara (5% IMQ cream) applied topically to murine skin, resulting in rapid onset of erythema, scaling, and thickening that can be quantified as disease severity indices and validated histologically.
-
TPA/Croton Oil Ear Edema and Dermatitis
The TPA (12-O-tetradecanoylphorbol-13-acetate) and croton oil-induced mouse ear edema model is a well-established acute cutaneous inflammation system used to evaluate topical anti-inflammatory activity by measuring edema formation, neutrophil infiltration, vascular permeability, and cytokine-mediated skin responses in vivo. The inflammatory response is triggered by topical application of phorbol esters (TPA) or croton oil constituents, leading to rapid activation of protein kinase C signaling, leukocyte recruitment, and increased vascular permeability, which can be quantified by ear thickness, weight, dye extravasation, and biochemical markers such as myeloperoxidase (MPO) activity and pro-inflammatory mediators in ear tissue homogenates. This model is widely used for screening anti-inflammatory agents, where reductions in edema and inflammatory biomarkers reflect suppression of acute dermal inflammation and immune cell infiltration. Histological evaluation typically confirms epidermal
-
Contact Hypersensitivity Dermatitis
Contact hypersensitivity (CHS) dermatitis is a T cell-mediated delayed-type (Type IV) immune reaction in which low-molecular-weight haptens applied to the skin bind host proteins to form complete antigens, triggering sensitization followed by a secondary inflammatory response upon re-exposure (elicitation phase), which is commonly quantified by ear swelling as a readout of skin inflammation in murine models. This model is widely used to study allergic contact dermatitis because it is antigen-specific, reproducible, and reflects key immunological events including dendritic cell activation, T cell priming in draining lymph nodes, and effector T cell-driven tissue inflammation. DNFB- and oxazolone-induced CHS models are standard systems for evaluating both acute and chronic T cell-dependent skin inflammation and for testing immunomodulatory interventions.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)